| __timestamp | Halozyme Therapeutics, Inc. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 79696000 | 3401685 |
| Thursday, January 1, 2015 | 93236000 | 4284228 |
| Friday, January 1, 2016 | 150842000 | 3581295 |
| Sunday, January 1, 2017 | 150643000 | 4838300 |
| Monday, January 1, 2018 | 150252000 | 24891534 |
| Tuesday, January 1, 2019 | 140804000 | 31347891 |
| Wednesday, January 1, 2020 | 34236000 | 17480747 |
| Friday, January 1, 2021 | 35672000 | 34710152 |
| Saturday, January 1, 2022 | 66607000 | 108459978 |
| Sunday, January 1, 2023 | 76363000 | 181563523 |
| Monday, January 1, 2024 | 79048000 | 176326321 |
Data in motion
In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Halozyme Therapeutics, Inc. and Opthea Limited have demonstrated contrasting trajectories in their R&D spending. From 2014 to 2023, Halozyme's R&D expenses peaked in 2016 and 2017, with a notable 150% increase from 2014, before experiencing a decline. In contrast, Opthea's R&D investments have shown a remarkable upward trend, culminating in a 5,300% increase by 2023 compared to 2014. This surge underscores Opthea's commitment to advancing its pipeline, particularly in ophthalmology. The data reveals a strategic shift in priorities, with Opthea outpacing Halozyme in recent years. As we look to the future, these investments will likely shape the next wave of breakthroughs in the biotech sector.
Comparing Innovation Spending: Amgen Inc. and Opthea Limited
Who Prioritizes Innovation? R&D Spending Compared for Zoetis Inc. and Halozyme Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
R&D Spending Showdown: Ascendis Pharma A/S vs Opthea Limited
Research and Development Investment: Jazz Pharmaceuticals plc vs Opthea Limited
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Pharming Group N.V.
Halozyme Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.: Strategic Focus on R&D Spending
R&D Spending Showdown: Halozyme Therapeutics, Inc. vs Perrigo Company plc
R&D Insights: How Halozyme Therapeutics, Inc. and ImmunityBio, Inc. Allocate Funds
R&D Insights: How Halozyme Therapeutics, Inc. and Mesoblast Limited Allocate Funds
Research and Development Expenses Breakdown: Madrigal Pharmaceuticals, Inc. vs Opthea Limited
Research and Development Investment: Opthea Limited vs Galapagos NV